Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The Inflation Reduction Act, which is expected to have wide-ranging implications for the pharmaceutical industry, will still need to go to the House of Representatives.
Results from two Amgen studies on Lumakras for lung cancer showed its ability to slow disease progression, although combining it with immunotherapy increased the risk for TRAEs.
Pfizer announced Monday that it is acquiring the hematology-focused company for $5.4 billion in order to bolster its presence in the multi-billion dollar rare disease market.
If replicated in humans, this technology could prolong organ health during major surgeries and improve the availability of donor organs.
If the FDA ultimately votes to approve Eli Lilly’s donanemab or Eisai’s lecanemab – both anti-amyloid beta (Aβ) antibodies – what impact will it make on Alzheimer’s disease?
Known as the Lone Star Bio Hotbed, Texas is home to multiple major players in the biopharma and biotech space and is currently a fast-growing hub for the life science industry.
The FDA has had a busy week, accepting drug applications, approving clinical trials and granting various special designations for Gamida Cell, Cellectis, Scynexis & more.
Shares of Global Blood Therapeutics are surging once again after reports indicate Pfizer is the mystery suitor for the company. Pfizer could potentially pay as much as $5 billion for the company.
With Monkeypox, COVID-19, Long COVID symptoms and persistent diseases like cancer and Alzheimer’s, the world is dealing with a lot right now. Here’s a look at the latest in clinical trial news.
You know it’s important to nail the interview with a potential employer, but it’s what you do after an interview that might really influence your chances of getting the job. Find out how in our guide.
This week’s highlights in neurological diseases include Acadia receiving a CRL for its ADP drug, Sosei and Neurocrine’s schizophrenia drug study moving on to Phase II.
A new discovery related to the mechanism of the danger signal adenosine triphosphate could influence how immunomodulators, such as vaccines and allergy medications, are formulated.
PRESS RELEASES
Head-to-Head Study Highlights Rocbrutinib as the World’s First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations
Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations